Cardiac arrhythmias. Rationale of drug therapy.
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000517:prevention & control; D001285:Atropine / Q000627:therapeutic use; D001919:Bradycardia / Q000188:drug therapy; D001949:Bretylium Compounds / Q000627:therapeutic use; D002301:Cardiac Glycosides / Q000627:therapeutic use; D004071:Digitalis Glycosides / Q000009:adverse effects / Q000627:therapeutic use; D004594:Electrophysiology; D004837:Epinephrine / Q000627:therapeutic use; D006801:Humans; D007545:Isoproterenol / Q000627:therapeutic use; D008012:Lidocaine / Q000009:adverse effects / Q000627:therapeutic use; D010672:Phenytoin / Q000627:therapeutic use; D011188:Potassium / Q000627:therapeutic use; D011342:Procainamide / Q000009:adverse effects / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use / Q000633:toxicity; D011802:Quinidine / Q000009:adverse effects / Q000627:therapeutic use; D012008:Recurrence; D013610:Tachycardia / Q000188:drug therapy
D000889:Anti-Arrhythmia Agents; D001949:Bretylium Compounds; D002301:Cardiac Glycosides; D004071:Digitalis Glycosides; D010672:Phenytoin; D001285:Atropine; D008012:Lidocaine; D011433:Propranolol; D011802:Quinidine; D011342:Procainamide; D007545:Isoproterenol; D011188:Potassium; D004837:Epinephrine